

Work Package 6: Plans for 2018

- **The Stakeholder Forum (SF)** acts as a key platform of interaction and consultation between all stakeholder groups. It aims to collect the inputs and viewpoints from patients' organisations, haematologists/clinicians, regulators and HTA bodies. Such engagement will ensure that there is a holistic view of what is required to enable better outcomes in HMs. It will be with the collaboration of WPs 2, 5, 6 and 7 that ensures the development of the HARMONY platform takes into consideration the needs of multiple stakeholders. The SF was set up in 2017.
 - In 2018, it will continue to bring its support and expertise to WP2 for the development of the Core Outcomes Set (COS) common to HMs and HM-specific. It will ensure HARMONY has access to constructive feedback from external but critical HARMONY stakeholders (Patients' Associations, HTA bodies, Regulatory Agencies and Payers). It will include input into the definition and selection of the
 - It will also support any consultations required by WP leads whenever appropriate
 - It will enable involvement of the pan-European patient organisations Myeloma Patients Europe, Acute Leukemia Advocates Network, Childhood Cancer International, CLL Advocates Network and International MDS Alliance across the HARMONY project to make sure HARMONY's work is focused around patients' needs and related evidence.
 - It will also ensure a close connection and follow up with Patients' Associations who might contribute data to the HARMONY consortium.

- **The Access Evidence Value Framework** aims at developing a HM-specific clinical and economic evidence framework that addresses regulator, HTA and payer requirements.
 - Following interviews done with HTA/ regulatory/ Payers in 2017, in 2018 these interviews will be analysed.
 - In parallel, extraction and analysis of key information from HTA/Regulatory dossiers related to HM drugs will be done
 - These steps will support the final objective of the overall project, which is the development of an evidence and analytic framework.

- **The Clinical Value Framework** aims at developing an instrument able to quantify the added therapeutic value of new technologies for the treatment of HMs, building from the experience of clinicians of WP2, patients, regulators, HTAs and other key stakeholders from the SF.
 - This task will be kicked-off in 2018 with involvement of all Task' partners.
 - From the kick-off meeting, plans and milestones for 2018 will be more detailed

About the HARMONY Alliance: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 51 partners. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs). The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

www.harmony-alliance.eu | @harmonyNetEU